The estimated Net Worth of Cynthia Sirard is at least $13.9 mil dollars as of 26 January 2024. Cynthia Sirard owns over 5,000 units of Leap Therapeutics Inc stock worth over $13,850 and over the last 5 years he sold LPTX stock worth over $0. In addition, he makes $0 as Chief Medical Officer at Leap Therapeutics Inc.
Cynthia has made over 1 trades of the Leap Therapeutics Inc stock since 2024, according to the Form 4 filled with the SEC. Most recently he exercised 5,000 units of LPTX stock worth $13,850 on 26 January 2024.
The largest trade he's ever made was exercising 5,000 units of Leap Therapeutics Inc stock on 26 January 2024 worth over $13,850. On average, Cynthia trades about 500 units every 0 days since 2020. As of 26 January 2024 he still owns at least 5,000 units of Leap Therapeutics Inc stock.
You can see the complete history of Cynthia Sirard stock trades at the bottom of the page.
Dr. Cynthia Sirard M.D. serves as Chief Medical Officer of the Company. She has served as our Chief Medical Officer since April 2020. Dr. Sirard has served as our Vice President of Clinical Research and Development since April 2012. Before joining Leap, Dr. Sirard served in clinical development and team leadership roles with Genzyme and Sanofi Oncology, following the merger with Genzyme. Prior to Genzyme, Dr. Sirard served as a medical director at Parexel International, a global clinical research organization. Dr. Sirard has more than eighteen years of global clinical development experience including optimization of strategic development and oversight of scientific, commercial and financial objectives for clinical programs in oncology, hematology and transplantation. She received her MD from Chicago Medical School and a BS from the University of Massachusetts at Amherst. She is a board certified Medical Oncologist with internal medicine and hematology/oncology training at Harvard Medical School at Beth Israel Deaconess Medical Center in Boston, Massachusetts.
Cynthia Sirard is 50, he's been the Chief Medical Officer of Leap Therapeutics Inc since 2020. There are 9 older and 1 younger executives at Leap Therapeutics Inc. The oldest executive at Leap Therapeutics Inc is James Cavanaugh, 82, who is the Independent Director.
Cynthia's mailing address filed with the SEC is C/O LEAP THERAPEUTICS, INC., 47 THORNDIKE STREET SUITE B1-1, CAMBRIDGE, MA, 02141.
Over the last 8 years, insiders at Leap Therapeutics Inc have traded over $0 worth of Leap Therapeutics Inc stock and bought 10,810,588 units worth $40,517,079 . The most active insiders traders include Advisors Llcperceptive Life..., Christopher Mirabelli y Ltd. Bei Gene,. On average, Leap Therapeutics Inc executives and independent directors trade stock every 142 days with the average trade being worth of $1,990,710. The most recent stock trade was executed by Christopher Mirabelli on 26 January 2024, trading 5,000 units of LPTX stock currently worth $13,850.
leap therapeutics (nasdaq: lptx) is a clinical-stage biopharmaceutical company acquiring and developing novel therapeutics at the leading edge of cancer research. for more information about leap therapeutics, visit http://www.leaptx.com or our public filings with the sec that are available via edgar at http://www.sec.gov or via http://www.investors.leaptx.com.
Leap Therapeutics Inc executives and other stock owners filed with the SEC include: